Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650091 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
NCT00650091 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 264 participants.
The verdict
NCT00650091, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
Study Summary
Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease that affects an individual's ability to breathe. In this randomized, double-blind, placebo-controlled trial, we assigned patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment to one of three groups - receiving a combination of prednisone, azathioprine, and NAC (combination therapy), NAC alone, or placebo - in a 1:1:1 ratio.
Interventions
- DRUG Placebo
- DRUG N-acetylcysteine (NAC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650091
The ClinicalTrials.gov registry entry for NCT00650091 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00650091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650091 about?
NCT00650091 is a clinical study titled "Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF". Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease that affects an individual's ability to breathe. In this randomized, double-blind, placebo-controlled trial, we assigned patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment to one of three group...
What is the current status of trial NCT00650091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2009-10. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00650091?
The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (NAC) (DRUG).
Who is sponsoring clinical trial NCT00650091?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.